Primary cardiac angiosarcoma with extensive visceral metastases: Utility of ¹⁸ F-fluorodeoxyglucose positron emission tomography-computed tomography in response assessment to sorafenib

Figures

• 

  Figure 1. (a) Pretherapy 18F fluorodeoxyglucose positron-emission tomography–computed tomography maximum intensity projection image showing focal increased fluorodeoxyglucose uptake in the thorax region (solid black arrow) suggestive of cardiac angiosarcoma. Dashed-red arrows show increased fluorodeoxyglucose uptake in the spleen suggestive of metastases. (b) Posttherapy 18F fluorodeoxyglucose positron-emission tomography–computed tomography maximum intensity projection image showing increased fluorodeoxyglucose uptake in the liver, spleen, thorax, and pelvis suggestive of metastases. (c) Trans-axial computed tomography image showing soft-tissue lesion in the right atrial appendage (d) Fused trans-axial positron-emission tomography–computed tomography image showing increased fluorodeoxyglucose uptake in the right atrial appendage suggestive of cardiac angiosarcoma

• 

  Figure 2. Fused axial pre-therapy positron-emission tomography–computed tomography image showing nodules in the right lung (a) which increased in size and fluorodeoxyglucose uptake in post-therapy scan. (b) Fused axial pre-therapy image (c) showing mildly fluorodeoxyglucose avid hypodense lesion in the spleen which increases in size and fluorodeoxyglucose avidity in post-therapy scan. (d) However, no significant change in Fluorodeoxyglucose avid liver lesion in segment V is seen. No significant fluorodeoxyglucose uptake is seen in the sternum (e) whereas post-therapy scan (f) shows increased fluorodeoxyglucose uptake in the sternum with no cortical changes suggestive of marrow metastases